Livedoid skin reaction probably due to imatinib therapy

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Imatinib is a crucial tyrosine kinase inhibitor used in treating Philadelphia chromosome-positive leukemias.
• Cutaneous adverse reactions are frequently reported with imatinib therapy.
• The Naranjo probability scale assesses the likelihood of adverse drug reactions.

Observation:

• Three male patients with chronic myeloid leukemia or acute lymphoblastic leukemia developed a unique livedoid skin rash during imatinib treatment.
• The skin eruptions varied in severity and response to interventions such as corticosteroids and dose adjustments.
• Two patients experienced disease progression or complications, with one succumbing to probable septic shock.

Findings:

• A probable relationship between imatinib therapy and the development of livedoid rash was indicated by the Naranjo probability scale in all three cases.
• The adverse skin reactions appeared to be dose-dependent, with recurrence upon reintroduction of imatinib.
• Common cutaneous adverse events associated with imatinib present with diverse clinical features.

Implications:

• Clinicians should be aware of the potential for imatinib to cause livedoid skin rashes.
• Prompt recognition and management, including dose modification or corticosteroid therapy, are essential for patients experiencing these adverse events.
• Close monitoring of patients on imatinib is crucial for early detection and intervention of dermatological side effects.